- Conditions
- Generalized Pustular Psoriasis
- Interventions
- Spesolimab
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Irvine, California • Fargo, North Dakota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Traumatic Brain Injury, Chronic Pain
- Interventions
- Self-Management #1, Self-Management #2
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 4
- States / cities
- Seattle, Washington • Tacoma, Washington
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- extended release dipyridamole 200mg/aspirin 25mg, 81mg aspirin
- Drug
- Lead sponsor
- Oklahoma Medical Research Foundation
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Crohn's Disease, Inflammatory Bowel Disease
- Interventions
- Corticosteroid
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Melanoma, Child
- Interventions
- FLARE
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 8 Years to 110 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Gouty Arthritis
- Interventions
- Canakinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Atopic Dermatitis
- Interventions
- Nevisense electrical impedance spectroscopy
- Device
- Lead sponsor
- Castle Biosciences Incorporated
- Industry
- Eligibility
- 12 Years to 89 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Las Vegas, Nevada • Portsmouth, New Hampshire + 1 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 63 Years
- Enrollment
- 1,014 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 132
- States / cities
- Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 107 more
- Conditions
- Fibrodysplasia Ossificans Progressiva (FOP)
- Interventions
- Not listed
- Lead sponsor
- The International FOP Association
- Other
- Eligibility
- Not listed
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2040
- U.S. locations
- 1
- States / cities
- North Kansas City, Missouri
- Conditions
- Prostate Cancer
- Interventions
- Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Palovarotene
- Drug
- Lead sponsor
- Clementia Pharmaceuticals Inc.
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 4
- States / cities
- San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Shoulder Pain
- Interventions
- Methylprednisolone (MPA), Triamcinolone Acetonide (TA)
- Drug
- Lead sponsor
- Campbell Clinic
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 421 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Germantown, Tennessee
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Andecaliximab, Placebo
- Drug
- Lead sponsor
- Ashibio Inc
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Adenocarcinoma of the Prostate, Stage IV Prostate Cancer
- Interventions
- AT-101, Bicalutamide, LHRH agent
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • New Brunswick, New Jersey + 1 more
- Conditions
- Non-small Cell Lung Cancer, Starting Pemetrexed Based Therapy, Unresectable Cancer
- Interventions
- Baseline 18F-thymidine (FLT) PET/CT, Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT "flare", Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Not listed
- Lead sponsor
- Clementia Pharmaceuticals Inc.
- Industry
- Eligibility
- Up to 65 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 2
- States / cities
- San Francisco, California • Philadelphia, Pennsylvania
- Conditions
- Uveitis
- Interventions
- Not listed
- Lead sponsor
- ChromoLogic, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Garetosmab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Nashville, Tennessee
- Conditions
- Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pembrolizumab
- Drug · Other · Procedure + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Rheumatoid Arthritis
- Interventions
- FLARE Intervention Group
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus
- Interventions
- Not listed
- Lead sponsor
- Lupus Research Alliance
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 3,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2035
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 15 more
- Conditions
- Allergic Rhinitis
- Interventions
- Fexofenadine
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 15 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept, DMARDs
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated, Crohn Disease in Remission
- Interventions
- Not listed
- Lead sponsor
- Viome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Bothell, Washington